"Vincamine"

Vincamine prevents lipopolysaccharide induced inflammation and oxidative stress via thioredoxin reductase activation in human corneal epithelial cells Lipopolysaccharide (LPS) induced keratitis is a progressive infectious ocular disease in which innate inflammatory responses often cause clinical tissue damage and vision loss. In this study, the potential protective effects of vincamine, a plant alkaloid used clinically as a peripheral vasodilator, against LPS induced inflammation and oxidative stress were investigated on human corneal epithelial cells (HCECs). HCECs were treated with LPS and vincamine at various concentrations. Cell viability, reactive oxygen species (ROS) levels, and the gene expression levels of interleukin-6 (IL-6), IL-8, IL-1β, TNF-α, transforming growth factor-β (TGF-β

Vinpocetine Attenuates the Osteoblastic Differentiation of Vascular Smooth Muscle Cells. Vascular calcification is an active process of osteoblastic differentiation of vascular smooth muscle cells; however, its definite mechanism remains unknown. Vinpocetine, a derivative of the alkaloid vincamine, has been demonstrated to inhibit the high glucose-induced proliferation of vascular smooth muscle

Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling Inflammatory responses play crucial roles in cerebral ischemia/reperfusion injury. Toll-like receptor 4 (TLR4) is an important mediator of the neuroinflammatory response to cerebral ischemia/reperfusion injury. Vinpocetine is a derivative of the alkaloid vincamine and exerts an anti

Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis Pathological cardiac remodeling, characterized by cardiac hypertrophy and fibrosis, is a pathological feature of many cardiac disorders that leads to heart failure and cardiac arrest. Vinpocetine, a derivative of the alkaloid vincamine, has been used for enhancing cerebral blood flow to treat

Pharmacokinetic aspects of the sublingual administration of vincamine. The sublingual absorption of vincamine used as tracer occurs in two successive absorption steps: true sublingual absorption and absorption in the gastrointestinal tract of the drug dissolved in the saliva and not absorbed through the buccal mucosa. This is confirmed by a pharmacokinetic study and simulation. These two

. Volunteers in the verum group received 10 ml of an ethanolic (vincamine free) eleutherococcus senticosus preparation, 3 times daily for 4 weeks. In the placebo, the eleutherococcus extract was substituted by additional wine, resulting in identical final concentrations of ethanol in both preparations. The purpose of the double-blind study was the demonstration of possible effects on the cellular immune

Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. The treatment of the acute phase of stroke creates a difficult problem to the clinician. The presently used drugs lead to controversial results. The progress in knowledge of the pathogenesis of cerebral damage underlines the determinant role of the metabolic deficits (4 ampoules of 3 ml = 60 mg vincamine p.d.) + glycerol, or glycerol + placebo administered by i.v. infusion. Clinically the results indicate a greater improvement of the neurological status (objectivated by a neurological scale) with vincamine treatment than with placebo. Statistically the analysis confirms the highly significant effect of vincamine on motility of lower and upper limbs (p less than

[Demonstrating the effectiveness of cerebroactive drugs in aged patients. Results of a randomized double-blind study of a vincamine containing special preparation]. The neuropsychiatric symptoms of old patients with disturbed cerebral metabolism or blood flow mostly lead to great individual difficulties and make those patients difficult to handle: in the family as well as in hospital such patients develop alienation, isolation and therefore adaptation to a social structure deteriorates with time. In the course of a test program for medicinal therapy of this syndrome we studied the efficacy of a vincamine containing formulation (Pervincamin forte retard or Pervincamin ampoules, respectively) on the symptoms of a chronical brain disturbance. The study was randomised double-blind. We found

[Double-blind comparison of vincamine and placebo in patients with presbyacusis (author's transl)]. 14-15-Dihydro-14beta-hydroxy-[3alpha,16alpha]-eburnamenine-14-carbonic acid methylester (vincamine, Vincapront) and placebo were compared in a double-blind trial, using daily doses of 60 mg p.o. in 30 out-patients suffering from peripheral and mainly centrally induced labyrinthine deafness . The result was checked by pure-tone and speech audiometry (monosyllabic word test) before and after treatment. The pure-tone audiometric test did not reveal any change in both groups while speech audiometry (monosyllabic word test) showed significant improvements in the vincamine group (p less than 0.004). Only random alterations occurred in the control group. Vincamine was well tolerated by all patients

[Double-blind controlled study of the effects of vincamine hydrochloride on some parameters of cardiovascular function in aged bronchopneumopathic patients].

[Controlled clinical study of the effects of Anasclerol in hospitalized patients with cerebrovascular disorders]. A double-blind clinical trial of vincamine hydrochloride and a known dihydrogenated ergotoxine derivative, administered i.m. for 10 days, was conducted on 2 groups of 10 hospitalised cerebrovascular patients. Hemiplegia was evaluated prior to treatment and on its 5th and 10th day , by a scoring system. Statistical assessment of the results and the clinical observations showed that vincamine hydrochloride can be usefully employed in the treatment of acute cerebrovascular accidents on account of its marked effectiveness and rapid action--these being attributable to its cerebral vasoregulatory and metabolic mechanism, and to increased availability due to salification of the basic molecule

Acute i.v. vincamine teprosilate administration: quantified investigation in elderly subjects. The EEG changes in elderly subjects with chronic cerebrovascular disorders (CCVD) are well known and have been described by many authors. Vincamine teprosilate (Teproside), a drug supposed to act on the electrical activity of the brain, has the properties of modifying and, to some extent, improving age -related changes. Ten subjects, whose age ranged from 60 to 70 years, underwent the trial. Each received 1 ampoule i.v. of the active drug and 1 ampoule of placebo (or vice versa) after a 48-hour wash-out period, according to a double-blind randomized schedule. EEG recordings were performed at time 0 and then 30 min, 1 h, 2 h, and 4 h after injection. A double effect of vincamine teprosilate could

Evaluation of the effect of vincamine teprosilate on behavioural performances of patients affected with chronic cerebrovascular disease. With a view to determining the efficacy of Teproside versus placebo in patients affected with cerebrovascular disease, 30 subjects, selected at the Montescano Medical Rehabilitation Centre, were randomly divided into two groups of 15 subjects each. After a two -week wash-out period, the first group was treated with placebo and the second with vincamine teprosilate (Teproside) at 120 mg daily, both for a period of 90 days. The assessment of each patient took place in two stages, one at the beginning and one at the end of treatment. It was performed according to both clinical criteria (including an interview with the patient and his family) and neuro

The effects of bromvincamine and vincamine on regional cerebral blood flow and mental functions in patients with multi-infarct dementia. The effects of vincamine and bromvincamine (BV 26-723) on mental functions and regional cerebral blood flow (rCBF) measured by the 133Xe inhalation method, were investigated in ten patients with mild to severe symptoms of multi-infarct dementia. The double blind cross over design included three treatment periods, each of 2 weeks' duration. The patients were drug free at the time of the first investigation in each treatment period. Then placebo, vincamine or bromvincamine was given orally (4 X 20 mg/day). Psychiatric evaluation, psychometric assessment and measurement of rCBF were done at start of medication and after 1 and 2 weeks during medication

Therapeutic efficacy of vincamine in dementia. This trial was performed to investigate the therapeutic efficacy of vincamine in the treatment of primary degenerative and vascular dementia. 152 male and female patients aged between 50 and 85 years from two psychogeriatric centers and two nursing homes were initially included in the trial and screened for eligibility. 142 patients completed the trial. Clinical diagnosis was established according to DSM-III-R criteria. Allocation of the patients to the primary degenerative dementia of the Alzheimer type (DAT) group or the multi-infarct dementia (MID) group was based on computed tomography scans, electroencephalographic findings and the Hachinski Ischemic Score. In a 12-week double-blind treatment either 30 mg vincamine or placebo was given

[Metabolic study of Vincamine in cranial trauma (author's transl)]. The metabolic effects of Vincamine were studied in eight cases of cranial trauma. The lactate/pyruvate ratio in venous blood and cerebrospinal fluid was observed for a period of six hours immediately following intravenous injection of Pervincamine (1 mg/kg) and the results compared with values obtained in the six hours following

[Clinical, psychological and neurophysiological results of double-blind study on vincamine-cromesilate in patients with cerebro-vascular insufficiency (author's transl)]. In a long-term double-blind cross-over design 26 patients with amnestic syndrome due to cerebro-vascular insufficiency were submitted to vincamine-cromesilate (Vincaryl) and placebo treatment. The efficiency of vincamine

Experimental cerebral infarction in Mongolian gerbils: effects of vincamine on lesion size, survival and behavior. Vincamine was administered to gerbils at doses of 0, 1, 2, 10 and 40 mg/kg/d to study its effect on survival, extent of ischemic brain lesion, locomotor activity, neurologic signs, stool production, and food and water intake after unilateral carotid occlusion. Drug and placebo were delivered by implantation of osmotic minipumps. The three most important criteria, increase in survival, reduction in cerebral lesion in survivors, and functional recovery of locomotor activity were all significantly improved by vincamine treatment at all doses. Since the lowest dose produced as much improvement as the higher doses it was concluded that increasing dose beyond 1 mg/kg/d was not beneficial

Classification and determination of pharmacodynamics of a new antihypoxidotic drug, vinconate, by pharmaco-EEG and psychometry. In a double-blind, placebo-controlled study the encephalotropic and psychotropic properties of both orally and intravenously administered doses of vinconate (OC 340)--a new vincamine analogue--were studied in 10 elderly subjects in their sixties by means of quantitative

Effects of vincamine on EEG sleep patterns in man: a pilot study. Nightly EEG recordings were performed in 8 healthy volunteers after intramuscular injections of placebo and 30 mg vincamine, under double-blind conditions, according to a crossover design. The single dose of vincamine induced a significant decrease in sleep Stage 4, a decrease in REM stages which approached statistical significance , and finally an increase in REM latency only in subjects showing low baseline values of this parameter. The above data confirm the awakening and antidepressant action of vincamine observed in previous studies in both animals and man.